MedMira Grants Stock Options to Directors and Officers



    HALIFAX, June 12 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that stock options will be granted to the company's
directors and officers, under the plan that was approved by shareholders at
its Annual General Meeting in January 2009. A total of 1,800,000 options to
purchase common shares of the Company will be issued. These options are at an
exercise price of $0.10 per share and are exercisable for a period of three
years. The grant is subject to the approval of the TSX Venture Exchange.
    "Shaped by the members of our board and executive team, MedMira is
steadfast in its strategic business initiatives that are driving the company
forward," said Dr. James Smith, Chairman, MedMira Inc. "Our officers and
directors are an engaged group of talented and experienced individuals. Their
expertise is essential at this time of growth within the Company, and granting
these stock options will provide the Company the ability to retain these key
personnel in a highly competitive market."

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Andrea Young, Corporate Communications,
MedMira, (902) 450-1588, ayoung@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890